Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

European Journal of Health Economics

Volumn 13, Issue 1, 2012, Pages 71-80

  Zaniolo, O ^a   Iannazzo, S ^a   Pradelli, L ^a   Miravitlles, M ^b  

^a AdRes Health Economics and Outcomes Research   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

COPD; Economic evaluation; Italy; Tiotropium; UPLIFT

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; EXPECTORANT AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OXYGEN; PLACEBO; TIOTROPIUM BROMIDE; XANTHINE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HUMAN; ITALY; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN THERAPY; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT RESPONSE;

AGED; BRONCHODILATOR AGENTS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; ITALY; MALE; MARKOV CHAINS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84858699283     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0285-8     Document Type: Article

References (61)

1. WHO - World Health Organization: World health report. WHO, Geneva (2000)
2. Stang, P., Lydick, E., Silberman, C., Kempel, A., Keating, E.T.: The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 117, 354S-359S (2000)
3. Feenstra, T.L., van Genugten, M.L., Hoogenveen, R.T., Wouters, E.F., Rutten-van Mölken, M.P.: The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am. J. Respir. Crit. Care Med. 164, 590-596 (2001)
4. Oostenbrink, J.B., Rutten-van Mölken, M.P.M.H.: Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 98, 883-891 (2004)
5. Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R.: Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123, 784-791 (2003)
6. Andersson, F., Borg, S., Jansson, S.A., Jonsson, A.C., Ericsson, A., Prütz, C., Rönmark, E., Lundbäck, B.: The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 96, 700-708 (2002)
7. Dal Negro, R., Rossi, A., Cerveri, I.: The burden of COPD in Italy: results from the Confronting COPD survey. Respir. Med. 97(Suppl C), S43-S50 (2003)
8. Koleva, D., Motterlini, N., Banfi, P., Garattini, L.: Healthcare costs of COPD in Italian referral centres: a prospective study. Respir. Med. 101, 2312-2320 (2007)
9. Lucioni, C., Donner, C., De Benedetto, F., Lusuardi, M., Mazzi, S., Paggiaro, P., Sanguinetti, C.: I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello Studio ICE (Italian Costs for Exacerbations in COPD). PharmacoEconomics - Italian Research Articles 7, 119-134 (2005)
10. Casaburi, R., Mahler, D.A., Jones, P.W., Wanner, A., San, P.G., ZuWallack, R.L., Menjoge, S.S., Serby, C.W., Witek, T.J.: A long-term evaluation of once-daily inhaled tiotropium bromide in chronic obstructive pulmonary disease. Eur. Respir. J. 19, 217-224 (2002)
11. Vincken, W., van Noord, J.A., Greefhorst, A.P.M., Bantje, T.A., Kesten, S., Korducki, L., Cornelissen, P.J.G.: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium bromide. Eur. Respir. J. 19, 209-216 (2002)
12. Brusasco, V., Hodder, R., Miravitlles, M., Korducki, L., Towse, L., Kesten, S.: Health outcomes following treatment for six months with once daily tiotropium bromide compared with twice daily salmeterol in patients with COPD. Thorax 58, 399-404 (2003)
13. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M.: A 4-year trial of tiotropium bromide in chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 1543-1554 (2008)
14. Dal Negro, R.W., Tognella, S., Tosatto, R., Dionisi, M., Turco, P., Donner, C.F.: Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes). Respir. Med. 102, 92-101 (2008)
15. Antonelli-Incalzi, R., Imperiale, C., Bellia, V., Catalano, F., Scichilone, N., Pistelli, R., Rengo, F.: Do GOLD stages of COPD severity really correspond to differences in health status? Eur. Respir. J. 22, 444-449 (2003)
16. Aaron, S.D., Vandemheen, K.L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., Bishop, G., Anthony, J., Cowie, R., Field, S., Hirsch, A., Hernandez, P., Rivington, R., Road, J., Hoffstein, V., Hodder, R., Marciniuk, D., McCormack, D., Fox, G., Cox, G., Prins, H.B., Ford, G., Bleskie, D., Doucette, S., Mayers, I., Chapman, K., Zamel, N., FitzGerald, M.: Tiotropium bromide in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146, 545-555 (2007)
17. Borrill, Z.L., Houghton, C.M., Tal-Singer, R., Vessey, S.R., Faiferman, I., Langley, S.J., Singh, D.: The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br. J. Clin. Pharmacol. 65, 244-252 (2008)
18. Freeman, D., Lee, A., Price, D.: Efficacy and safety of tiotropium bromide in COPD patients in primary care-the SPiRiva Usual CarE (SPRUCE) study. Respir Res 8, 45 (2007)
19. Verkindre, C., Bart, F., Aguilaniu, B., Fortin, F., Guérin, J., Le Merre, C., Iacono, P., Huchon, G.: The effect of tiotropium bromide on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 73, 420-427 (2006)
20. Maltais, F., Hamilton, A., Marciniuk, D., Hernandez, P., Sciurba, F.C., Richter, K., Kesten, S., O'Donnell, D.: Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium bromide in patients with COPD. Chest 128, 1168-1178 (2005)
21. Niewoehner, D.E., Rice, K., Cote, C., Paulson, D., Cooper, J.A.D.J., Korducki, L., Cassino, C., Kesten, S.: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium bromide, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 143, 317-326 (2005)
22. O'Donnell, D.E., Flüge, T., Gerken, F., Hamilton, A., Webb, K., Aguilaniu, B., Make, B., Magnussen, H.: Effects of tiotropium bromide on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 23, 832-840 (2004)
23. van Noord, J.A., Aumann, J.L., Janssens, E., Verhaert, J., Smeets, J.J., Mueller, A., Cornelissen, P.J.G.: Effects of tiotropium bromide with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129, 509-517 (2006)
24. ISTAT - National Institute of Statistics. Mortality tables of the general population 2006. Available online at http://demo.istat.it/unitav/index.html? lingua=ita. Last accessed Apr 2009
25. WHO/Europe: European health for all database (HFA-DB). Available on line at http://data.euro.who.int/hfadb/tables/tableC.php?w=1280&h=1024. Last accessed Apr 2008
26. Lange, P., Nyboe, J., Appleyard, M., Jensen, G., Schnohr, P.: Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 45, 579-585 (1990)
27. Sta° hl, E., Lindberg, A., Jansson, S., Rönmark, E., Svensson, K., Andersson, F., Löfdahl, C., Lundbäck, B.: Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 3, 56 (2005)
28. Ferrario, M.M., Fornari, C., Bolognesi, L., Gussoni, M.T., Benedetti, M., Sega, R., Borchini, R., Cesana, G.: Recent time trends of myocardial infarction rates in northern Italy. Results from the MONICA and CAMUNI registries in Brianza: 1993-1994 versus 1997-1998. Ital. Heart J. Suppl. 4, 651-657 (2003)
29. ANMCO Consensus Conference.: Il percorso assistenziale del paziente con scompenso cardiaco. G. Ital. Cardiol. Giugno 7 (2006)
30. Sidney, S., Sorel, M., Quesenberry, C.P.J., DeLuise, C., Lanes, S., Eisner, M.D.: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser permanente medical care program. Chest 128, 2068-2075 (2005)
31. Italian Specialist Tariffs. Nomenclatore Tariffario Nazionale D.M. 22 luglio 1996
32. Nomenclatore Tariffario Nazionale: DRG Tariffs. DMS 12/09/2006. Supplemento Ordinario alla Gazzetta Ufficiale n. 289 del 13/12/2006
33. HDR-Hospital Discharge Records database. Available online at http://www.ministerosalute.it/programmazione/sdo/ric-informazioni/default.jsp. Last accessed Apr 2009
34. Italian Drug Formulary: Informatore Farmaceutico, 69a edizione. Elsevier Masson (2009)
35. World Health Organization: WHO/CHOosing interventions that are cost/effective (WHO-CHOICE), 2000. Available online at http://www.who.int/ choice. Last accessed Dec 2008
36. Laupacis, A., Feeny, D., Detsky, A.S., Tugwell, P.X.: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146, 473-481 (1992)
37. Tosteson, A.N.: Quality of life in the economic evaluation of osteoporosis prevention and treatment. Spine (Phila Pa 1976) 22:58S-62S (1997)
38. Kanis, J.A., Jonsson, B.: Economic evaluation of interventions for osteoporosis. Osteoporos. Int. 13, 765-767 (2002)
39. Raftery, J.: NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 323, 1300-1303 (2001)
40. ISTAT - National Institute of Statistics: Historical series of per capita gross domestic product (GDP) (1970-2007). Available online at http://www.istat.it/conti/. Last accessed Feb 2009
41. Oostenbrink, J.B., Rutten-van Mölken, M.P.M.H., Monz, B.U., FitzGerald, J.M.: Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8, 32-46 (2005)
42. Rutten-van Mölken, M.P.M.H., Oostenbrink, J.B., Miravitlles, M., Monz, B.U.: Modelling the 5-year cost effectiveness of tiotropium bromide, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 8, 123-135 (2007)
43. Maniadakis, N., Tzanakis, N., Fragoulakis, V., Hatzikou, M., Siafakas, N.: Economic evaluation of tiotropium bromide and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr. Med. Res. Opin. 22, 1599-1607 (2006)
44. Nishimura S, Kobayashi M, Hasegawa T.: Cost-effectiveness analysis of tiotropium bromide for chronic obstructive pulmonary disease (COPD) patients in Japan. ISPOR 10th Annual International Meeting, 2005. Washington, DC, USA
45. Brosa, M., Díaz, S., Miravitlles, M., Gonzalez-Rojas, N., Nieves, D.: Cost-effectiveness analysis of tiotropium bromide in the treatment of chronic obstructive pulmonary disease (COPD) patients in Spain. ISPOR 12th Annual European Congress, 2009. Paris, France
46. De Lucas, P., Rodríguez, J., Gobartt, E., Soto, J., Martin, A.: Pharmacoeconomic evaluation of tiotropium bromide in the treatment of patients with chronic obstructive pulmonary disease in Spain. ISPOR 8th European Congress, 2005. Florence, Italy
47. Onukwugha, E., Mullins, C.D., DeLisle, S.: Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium bromide at the veterans affairs health care system. Value Health 11, 980-988 (2008)
48. Schramm, W., Haake, D., Brandt, A.: Economic value of tiotropium bromide in the treatment of chronic obstructive pulmonary disease. Praxis (Bern 1994) 94:1803-1810 (2005)
49. Lee, K., Phua, J., Lim, T.: Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Respir. Med. 100, 2190-2196 (2006)
50. Oba, Y.: Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care 15, 226-232 (2009)
51. Earnshaw, S.R., Wilson, M.R., Dalal, A.A., Chambers, M.G., Jhingran, P., Stanford, R., Mapel, D.W.: Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir. Med. 103, 12-21 (2009)
52. Spencer, M., Briggs, A.H., Grossman, R.F., Rance, L.: Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23, 619-637 (2005)
53. Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R.: Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121, 1449-1455 (2002)
54. Ram, F.S.F., Wedzicha, J.A., Wright, J., Greenstone, M.: Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ 329, 315 (2004)
55. Jahnz-Rozyk, K.M., Targowski, T., From, S.: Costs of COPD exacerbations in Poland (results of the pilot study). ISPOR 9th Annual European Congress. Copenhagen, Denmark
56. Spannheimer, A., Schlegel, C., Reitberger, U., Welsch, R., Ruckdaeschel, S.: Costs of COPD in Germany - results of a costof illness study. ISPOR 6th Annual European Congress. Barcelona, Spain
57. Halpin, D.M.G., Miravitlles, M.: Chronic obstructive pulmonary disease. The Disease and Its Burden to Society. Proc Am Thorac Soc 3, 619-623 (2006)
58. Seemungal, T.A.R., Hurst, J.R., Wedzicha, J.A.: Exacerbation rate, health status and mortality in COPD-a review of potential interventions. Int J Chron Obstruct Pulmon Dis 4, 203-223 (2009)
59. FitzGerald, J.M., Haddon, J.M., Bradly-Kennedy, C., Kuramoto, L., Ford, G.T.: Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J 14, 145-152 (2007)
60. Mantovani, L.G., Mannino, S., Donner, C.E., et al.: The cost of COPD: Results from the SIRIBO (Studio Italiano sulle Riacutizzazioni Infettive delle Bronchiti). Eur. Respir. J. 20(suppl 38) (2002)
61. Ferrara Statistical Service. Available on line at http://servizi.comune. fe.it/attach/statistica/docs/informanumeri7-04abitudine-al-fumo-e-obesita.pdf (2003). Last accessed Apr 2009\